JP2023518356A - Ｃｏｖｉｄ－１９関連状態の治療のための方法 - Google Patents

Ｃｏｖｉｄ－１９関連状態の治療のための方法 Download PDF

Info

Publication number
JP2023518356A
JP2023518356A JP2022554956A JP2022554956A JP2023518356A JP 2023518356 A JP2023518356 A JP 2023518356A JP 2022554956 A JP2022554956 A JP 2022554956A JP 2022554956 A JP2022554956 A JP 2022554956A JP 2023518356 A JP2023518356 A JP 2023518356A
Authority
JP
Japan
Prior art keywords
patient
administering
thrombosis
fostamatinib
covid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554956A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021183790A5 (enExample
Inventor
マスダ，エステバン
マルコフツォフ，バディム
Original Assignee
ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライジェル ファーマシューティカルズ， インコーポレイテッド filed Critical ライジェル ファーマシューティカルズ， インコーポレイテッド
Priority claimed from PCT/US2021/021951 external-priority patent/WO2021183790A1/en
Publication of JP2023518356A publication Critical patent/JP2023518356A/ja
Publication of JPWO2021183790A5 publication Critical patent/JPWO2021183790A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
JP2022554956A 2020-03-12 2021-03-11 Ｃｏｖｉｄ－１９関連状態の治療のための方法 Pending JP2023518356A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062988876P 2020-03-12 2020-03-12
US62/988,876 2020-03-12
US202063038570P 2020-06-12 2020-06-12
US63/038,570 2020-06-12
PCT/US2021/021951 WO2021183790A1 (en) 2020-03-12 2021-03-11 Method for treatment of covid-19-associated conditions

Publications (2)

Publication Number Publication Date
JP2023518356A true JP2023518356A (ja) 2023-05-01
JPWO2021183790A5 JPWO2021183790A5 (enExample) 2024-03-21

Family

ID=77665493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554956A Pending JP2023518356A (ja) 2020-03-12 2021-03-11 Ｃｏｖｉｄ－１９関連状態の治療のための方法

Country Status (13)

Country Link
US (1) US12263180B2 (enExample)
EP (1) EP4117728A4 (enExample)
JP (1) JP2023518356A (enExample)
KR (1) KR20220152293A (enExample)
CN (1) CN115768474A (enExample)
AU (1) AU2021234316A1 (enExample)
BR (1) BR112022018235A2 (enExample)
CA (1) CA3175089A1 (enExample)
IL (1) IL296352A (enExample)
JO (1) JOP20220218A1 (enExample)
MX (1) MX2022011278A (enExample)
PE (1) PE20230996A1 (enExample)
PH (1) PH12022552539A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023194840A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
CN116440117A (zh) * 2023-06-14 2023-07-18 四川省医学科学院·四川省人民医院 甲磺酸萘莫司他在制备治疗肾损伤或肾功能不全药物中的应用
CN116650507A (zh) * 2023-06-28 2023-08-29 中国人民解放军军事科学院军事医学研究院 福它替尼在制备治疗放射性肺纤维化药物中的应用
CN118649237A (zh) * 2024-06-13 2024-09-17 高维医药(杭州)有限公司 S蛋白或p4hb蛋白作为靶点在制备预防或治疗新冠感染相关性凝血病变的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063794A2 (en) * 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US20160060260A1 (en) * 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
US20230165842A1 (en) * 2020-04-22 2023-06-01 Aivivo Ltd New uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
EP2420505A1 (en) 2006-11-21 2012-02-22 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4- pyrimidinediamine compounds and their uses
UA102825C2 (ru) 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
WO2015116729A2 (en) 2014-01-28 2015-08-06 Emergent Product Development Seattle, Llc Anti-cd37 antibody and anti-cd20 antibody combination therapy for treatment of b-cell malignancies and disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063794A2 (en) * 2002-02-01 2003-08-07 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US20160060260A1 (en) * 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
US20230165842A1 (en) * 2020-04-22 2023-06-01 Aivivo Ltd New uses

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Anonymous: DOD Supports Phase Ill Clinical Trial Using Fostamatinib(TAVALISSE) Against COVID-19", [ONLINE], JPN6025016539, 29 January 2021 (2021-01-29), ISSN: 0005710724 *
AHMED NADEEM ET AL.: ""Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 68, JPN6025016544, March 2019 (2019-03-01), pages 39 - 47, XP093138558, ISSN: 0005710721, DOI: 10.1016/j.intimp.2018.12.062 *
ASTRAZENECA: "A Study of Fostamatinib in Subjects With Impaired KidneyFunction", CLINICALTRIALS.GOV, JPN6025016538, 16 June 2011 (2011-06-16), ISSN: 0005710729 *
JEFFREY R STRICH ET AL.: ""Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potent", THE JOURNAL OF INFECTIOUS DISEASES, vol. 223, no. 6, JPN6025016542, 24 December 2020 (2020-12-24), pages 981 - 984, XP093138725, ISSN: 0005710723, DOI: 10.1093/infdis/jiaa789 *
LANCET, vol. 395, JPN6025016543, 15 February 2020 (2020-02-15), pages 497 - 506, ISSN: 0005710722 *
MARIA KOST-ALIMOVA ET AL.: ""A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Ra", CELL REPORTS MEDICINE, vol. 1, no. 8, JPN6025016537, November 2020 (2020-11-01), pages 100137, XP093138923, ISSN: 0005580497, DOI: 10.1016/j.xcrm.2020.100137 *
NATHAN T. CONNELL ET AL.: ""Fostamatinib for the treatment of chronic immune thrombocytopenia"", BLOOD, vol. 133, no. 19, JPN6025016545, 9 May 2019 (2019-05-09), pages 2027 - 2030, ISSN: 0005710730 *
SHITAO RAO ET AL.: ""Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative", DIABETES CARE, vol. 43, no. 7, JPN6025016536, 19 May 2020 (2020-05-19), pages 1416 - 1426, ISSN: 0005710728 *
SOVAN SAHA ET AL.: ""Is Fostamatinib a possible drug for COVID-19? − A computational study"", OSF PREPRINTS, JPN6025016541, 15 August 2020 (2020-08-15), ISSN: 0005710725 *
WOLFGANG DUMMER ET AL.: ""Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prev", BLOOD, vol. 136, no. 1, JPN6025016540, 5 November 2020 (2020-11-05), pages 35 - 35, ISSN: 0005710726 *

Also Published As

Publication number Publication date
JOP20220218A1 (ar) 2023-01-30
IL296352A (en) 2022-11-01
PE20230996A1 (es) 2023-06-26
US20210283152A1 (en) 2021-09-16
BR112022018235A2 (pt) 2022-12-20
US12263180B2 (en) 2025-04-01
KR20220152293A (ko) 2022-11-15
EP4117728A1 (en) 2023-01-18
PH12022552539A1 (en) 2024-01-22
EP4117728A4 (en) 2024-04-17
CN115768474A (zh) 2023-03-07
AU2021234316A1 (en) 2022-10-13
MX2022011278A (es) 2022-12-15
CA3175089A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
JP2023518356A (ja) Ｃｏｖｉｄ－１９関連状態の治療のための方法
DK2185515T3 (en) DERIVATIVES OF 1-PHENYL-2-PYRIDINYLALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS
WO2021183790A1 (en) Method for treatment of covid-19-associated conditions
US10125100B2 (en) Kinase inhibitors
AU2002358713B2 (en) Combination of cytochrome P450 dependent protease inhibitors
JP2013531062A (ja) アルドース還元酵素阻害剤および同使用方法
RU2564414C2 (ru) Новый агонист ер4
TW202327615A (zh) 治療對呼吸道病毒感染的過度免疫反應之方法
JPWO2002020540A1 (ja) アデノシン誘導体及びその用途
JP2017509665A (ja) 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類
JP6787926B2 (ja) 肺高血圧症の治療方法
EA049122B1 (ru) Способ лечения связанных с covid-19 состояний
HK40090264A (zh) 用於治疗covid-19相关病症的方法
EP4399208A1 (en) Irak inhibitor for treating cytokine release-related conditions associated with infection by a respiratory virus
WO2024182776A1 (en) Use of a syk inhibitor for the treatment of sickle cell disease
ZA200006036B (en) Reduced partice size form of 1-(6-chloronaphth-2-ylsulphonyl)-4-[4-(4-pyridyl) benzoyl] piperazine.
RU2431484C2 (ru) Диарилмочевина для лечения легочной гипертензии
MXPA00010676A (en) Reduced particle size form of 1-(6-chloronaphth-2- ylsulphonyl) -4-[4-(4pyridyl) benzoyl]piperazine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251020